Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts


  Free Subscription


2 Acta Haematol
3 Ann Hematol
1 Biochem Biophys Res Commun
17 Blood
1 BMC Cancer
1 BMC Genomics
9 Br J Haematol
1 Eur J Haematol
1 Gene
1 Genes Chromosomes Cancer
2 J Clin Oncol
2 J Pediatr Hematol Oncol
8 Leuk Lymphoma
3 Leuk Res
1 Oncol Rep
4 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Acta Haematol

    No Mutation Left Behind: The Impact of Reporting Recurrent Genetic Abnormalities on Outcomes of Patients with Acute Myeloid Leukemia.
    Acta Haematol. 2018;139:128-130.
    PubMed     Text format    

  2. BARON BW, Thirman MJ, Giurcanu MC, Baron JM, et al
    Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study.
    Acta Haematol. 2018;139:132-139.
    PubMed     Text format     Abstract available

    Ann Hematol

  3. ZHAO HY, Song Y, Cao XN, Qin YZ, et al
    Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.
    Ann Hematol. 2018 Feb 10. pii: 10.1007/s00277-018-3253.
    PubMed     Text format     Abstract available

  4. NAKAYAMA S, Matsuda M, Adachi T, Sueda S, et al
    Adult T cell leukemia/lymphoma with different pathological features in each tumor site.
    Ann Hematol. 2018 Feb 9. pii: 10.1007/s00277-018-3272.
    PubMed     Text format    

  5. HIDALGO LOPEZ JE, Carballo-Zarate A, Verstovsek S, Wang SA, et al
    Bone marrow findings in blast phase of polycythemia vera.
    Ann Hematol. 2018;97:425-434.
    PubMed     Text format     Abstract available

    Biochem Biophys Res Commun

  6. WANG J, Xu Y, Wan H, Hu J, et al
    Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress.
    Biochem Biophys Res Commun. 2018 Feb 8. pii: S0006-291X(18)30286.
    PubMed     Text format     Abstract available


  7. PILLAI V, Maude SL
    CART attack.
    Blood. 2017;130:229.
    PubMed     Text format    

  8. MAGINA KN, Pregartner G, Zebisch A, Wolfler A, et al
    Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Blood. 2017;130:946-948.
    PubMed     Text format    

  9. AHCI M, Toffalori C, Bouwmans E, Crivello P, et al
    A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.
    Blood. 2017;130:1270-1273.
    PubMed     Text format    

  10. SELIMOGLU-BUET D, Badaoui B, Benayoun E, Toma A, et al
    Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
    Blood. 2017;130:832-835.
    PubMed     Text format    

  11. BLACKBURN NB, Marthick JR, Banks A, Charlesworth JC, et al
    Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.
    Blood. 2017;130:86-88.
    PubMed     Text format    

  12. KITAMURA N, Nakanishi T, Yoshida Y, Higashi T, et al
    HTLV-I-associated posttransplant lymphoproliferative disorder following virus transmission from recipient to donor cells.
    Blood. 2017;130:84-86.
    PubMed     Text format    

  13. RIGOLIN GM, Cavallari M, Quaglia FM, Formigaro L, et al
    In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
    Blood. 2017;129:3495-3498.
    PubMed     Text format    

  14. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.
    PubMed     Text format    

  15. ZHANG Y, Gao Y, Zhang H, Zhang J, et al
    PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
    Blood. 2018 Feb 6. pii: blood-2017-11-817510. doi: 10.1182/blood-2017-11-817510.
    PubMed     Text format     Abstract available

  16. YUN S, Zhang L, Patel MR, Knepper TC, et al
    Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL).
    Blood. 2018 Feb 5. pii: blood-2017-11-819276. doi: 10.1182/blood-2017-11-819276.
    PubMed     Text format    

  17. O'BRIEN S, Furman RR, Coutre S, Flinn IW, et al
    Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.
    Blood. 2018 Feb 2. pii: blood-2017-10-810044. doi: 10.1182/blood-2017-10-810044.
    PubMed     Text format     Abstract available

  18. MURAKAMI N, Okuno Y, Yoshida K, Shiraishi Y, et al
    Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Blood. 2018 Feb 2. pii: blood-2017-07-798157. doi: 10.1182/blood-2017-07-798157.
    PubMed     Text format     Abstract available

  19. BHAGWAT AS, Lu B, Vakoc CR
    Enhancer dysfunction in leukemia.
    Blood. 2018 Feb 9. pii: blood-2017-11-737379. doi: 10.1182/blood-2017-11-737379.
    PubMed     Text format     Abstract available

  20. WIERZ M, Pierson S, Guyonnet L, Viry E, et al
    Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
    Blood. 2018 Feb 13. pii: blood-2017-06-792267. doi: 10.1182/blood-2017-06-792267
    PubMed     Text format    

  21. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    

  22. LECLERC M, Peffault de Latour R, Michallet M, Blaise D, et al
    Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
    Blood. 2017;129:1227-1230.
    PubMed     Text format    

  23. ALDOSS I, Song JY
    Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation.
    Blood. 2017;129:1231.
    PubMed     Text format    

    BMC Cancer

  24. BI L, Zhou B, Li H, He L, et al
    A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
    BMC Cancer. 2018;18:182.
    PubMed     Text format     Abstract available

    BMC Genomics

  25. CARIGNANO HA, Roldan DL, Beribe MJ, Raschia MA, et al
    Genome-wide scan for commons SNPs affecting bovine leukemia virus infection level in dairy cattle.
    BMC Genomics. 2018;19:142.
    PubMed     Text format     Abstract available

    Br J Haematol

  26. CHAN KL, Blombery P, Jones K, Lade S, et al
    Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.
    Br J Haematol. 2017;177:324-328.
    PubMed     Text format    

  27. MAGEE JA
    Comment on: Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
    Br J Haematol. 2017;176:5-6.
    PubMed     Text format    

    Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
    Br J Haematol. 2017;176:337-340.
    PubMed     Text format    

    "The Second Time is Sweeter After All".
    Br J Haematol. 2017;176:511-512.
    PubMed     Text format    

    Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?
    Br J Haematol. 2017;177:169-170.
    PubMed     Text format    

    Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
    Br J Haematol. 2017;178:347-348.
    PubMed     Text format    

  32. MALONE A, Smith OP
    Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
    Br J Haematol. 2017;179:179-181.
    PubMed     Text format    

    From remission to cure: bypass or detour?
    Br J Haematol. 2018;180:317-318.
    PubMed     Text format    

  34. GOCKE CD, Gladstone DE
    The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Br J Haematol. 2018;180:7-8.
    PubMed     Text format    

    Eur J Haematol

  35. ROBAK T, Blonski J, Skotnicki AB, Piotrowska M, et al
    Rituximab, cladribine and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
    Eur J Haematol. 2018 Feb 10. doi: 10.1111/ejh.13042.
    PubMed     Text format     Abstract available


  36. ASIK A, Kayabasi C, Ozmen Yelken B, Yilmaz Susluer S, et al
    Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line.
    Gene. 2018;647:213-220.
    PubMed     Text format     Abstract available

    Genes Chromosomes Cancer

  37. ROUSSY M, Bilodeau M, Jouan L, Tibout P, et al
    NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy.
    Genes Chromosomes Cancer. 2018 Feb 10. doi: 10.1002/gcc.22532.
    PubMed     Text format     Abstract available

    J Clin Oncol

  38. BHAYADIA R, Krowiorz K, Haetscher N, Jammal R, et al
    Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
    J Clin Oncol. 2018 Feb 12:JCO2017752204. doi: 10.1200/JCO.2017.75.2204.
    PubMed     Text format     Abstract available

  39. BERMAN E, Druker BJ, Burwick R
    Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy.
    J Clin Oncol. 2018 Feb 15:JCO2017772574. doi: 10.1200/JCO.2017.77.2574.
    PubMed     Text format    

    J Pediatr Hematol Oncol

  40. TUFEKCI O, Erdem M, Oren H, Yilmaz S, et al
    Cup-like Blasts in 2 Pediatric Patients With NPM-1-Positive Acute Myeloid Leukemia.
    J Pediatr Hematol Oncol. 2018 Feb 9. doi: 10.1097/MPH.0000000000001110.
    PubMed     Text format     Abstract available

  41. FERRI GM, Guastadisegno CM, Intranuovo G, Cavone D, et al
    Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia.
    J Pediatr Hematol Oncol. 2018 Feb 9. doi: 10.1097/MPH.0000000000001105.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  42. ALVAREZ E, Muffly L, Li Q, Brunson A, et al
    Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.
    Leuk Lymphoma. 2018 Feb 9:1-3. doi: 10.1080/10428194.2018.1427856.
    PubMed     Text format    

  43. DERRIEUX C, Freynet N, Frayfer J, Delabesse E, et al
    A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1430796.
    PubMed     Text format    

  44. ZAJAC-SPYCHALA O, Pawlak M, Karmelita-Katulska K, Pilarczyk J, et al
    Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate.
    Leuk Lymphoma. 2018 Feb 9:1-10. doi: 10.1080/10428194.2018.1434879.
    PubMed     Text format     Abstract available

  45. SMIRNIKHINA SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, et al
    Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1434880.
    PubMed     Text format    

  46. KRUPAR R, Schreiber C, Offermann A, Lengerke C, et al
    In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-4. doi: 10.1080/10428194.2018.1434883.
    PubMed     Text format    

  47. KARANTANOU C, Godavarthy PS, Krause DS
    Targeting the bone marrow microenvironment in acute leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434886.
    PubMed     Text format     Abstract available

  48. IKAWA Y, Nishimura R, Maeba H, Fujiki T, et al
    Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.
    Leuk Lymphoma. 2018 Feb 12:1-3. doi: 10.1080/10428194.2018.1434885.
    PubMed     Text format    

  49. VAN DE LOUW A, Desai RJ, Zhu J, Claxton DF, et al
    Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-8. doi: 10.1080/10428194.2018.1435874.
    PubMed     Text format     Abstract available

    Leuk Res

  50. HEINRICHS A, Dessars B, El Housni H, Pluymers W, et al
    Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
    Leuk Res. 2018;67:27-31.
    PubMed     Text format     Abstract available

  51. TOSIC N, Petrovic I, Grujicic NK, Davidovic S, et al
    Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia.
    Leuk Res. 2018;67:32-38.
    PubMed     Text format     Abstract available

  52. BLAKLEY MP, Dutcher JP, Wiernik PH
    Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature.
    Leuk Res. 2018;67:39-44.
    PubMed     Text format     Abstract available

    Oncol Rep

  53. MA X, Zhou X, Qu H, Ma Y, et al
    TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells.
    Oncol Rep. 2018 Feb 7. doi: 10.3892/or.2018.6249.
    PubMed     Text format     Abstract available

    PLoS One

  54. GRUNDY M, Seedhouse C, Jones T, Elmi L, et al
    Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
    PLoS One. 2018;13:e0190682.
    PubMed     Text format     Abstract available

  55. OHATA Y, Tsuchiya M, Hirai H, Yamaguchi S, et al
    Leukemia inhibitory factor produced by fibroblasts within tumor stroma participates in invasion of oral squamous cell carcinoma.
    PLoS One. 2018;13:e0191865.
    PubMed     Text format     Abstract available

  56. KOKHAEI P, Hojjat-Farsangi M, Mozaffari F, Moshfegh A, et al
    Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.
    PLoS One. 2018;13:e0192839.
    PubMed     Text format     Abstract available

  57. LANGE A, Jaskula E, Lange J, Dworacki G, et al
    The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.
    PLoS One. 2018;13:e0190525.
    PubMed     Text format     Abstract available

    Proc Natl Acad Sci U S A

  58. MULLER F, Cunningham T, Stookey S, Tai CH, et al
    5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
    Proc Natl Acad Sci U S A. 2018 Feb 5. pii: 1714512115.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.